KEFLEX (cephalexin) by Pragma Bio is [see microbiology ( )] . First approved in 1971.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
KEFLEX (cephalexin) is an oral first-generation cephalosporin antibiotic approved in 1971 that inhibits bacterial cell wall synthesis. It is used to treat a broad range of gram-positive and some gram-negative bacterial infections including skin, respiratory, urinary tract, and bone infections. This generic-equivalent product remains a foundational agent in primary care and community settings.
As an off-patent antibiotic with approaching loss of exclusivity, the brand team is likely small and focused on maintaining market presence against generic competition.
[see Microbiology ( )] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Oral Amoxicillin and Cephalexin PK/PD in Neonates
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
A Study of Cephalexin Liquid in Healthy Participants
A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants
A Study of Cephalexin Suspension in Healthy Participants
Worked on KEFLEX at Pragma Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job postings and approaching loss of exclusivity, KEFLEX offers limited career upside; roles are primarily defensive commercial positions focused on generic containment and market share retention. Career development and advancement are constrained on a mature, off-patent asset.